Image Credit: thodonal/123rf.com
A new screening tool designed to identify early signs of Alzheimer’s disease has shown promising results in a recent study conducted by researchers at the University of Bath. The Fastball test, which takes just three minutes, utilizes advanced brainwave technology to detect subtle memory issues linked to Alzheimer’s, potentially enabling earlier diagnosis and treatment.
The Fastball test operates as a form of electroencephalogram (EEG). Small sensors are placed on the scalp to monitor electrical activity in the brain while participants view a rapid succession of images on a screen. Initially, participants are shown eight familiar images, such as a ball or a chair, and asked to name them. During the subsequent test, hundreds of images flash on the screen, with every fifth image being one of the previously shown pictures. Importantly, participants are not required to actively recall or identify these familiar images. Instead, the brain’s automatic responses indicate recognition, which can reveal early memory issues.
In trials involving 54 healthy adults and 52 patients with mild cognitive impairment (MCI), results indicated that those with amnestic MCI—who face a higher risk of developing Alzheimer’s—exhibited weaker brain responses compared to their healthier counterparts. This suggests the test’s potential to identify individuals at risk of Alzheimer’s long before traditional diagnostic methods would typically recognize the condition.
Currently, Alzheimer’s disease is often diagnosed after significant symptoms have emerged, making early detection crucial for the effective use of emerging treatments. Drugs like donanemab and lecanemab have shown the greatest efficacy in the early stages of the disease, highlighting the importance of timely diagnosis.
The Fastball test stands out for its accessibility, as it can be conducted in participants’ homes, reducing anxiety and intimidation often associated with clinical settings. The trial results were published in the journal Brain Communications, and further studies are planned to validate the findings and assess the test’s effectiveness over time.
While experts acknowledge the test as a promising first step towards a clinically useful tool, they emphasize the need for larger and more diverse studies. Research will also need to explore how brainwave testing can complement other diagnostic methods, such as cognitive assessments and blood tests.
Alzheimer’s disease currently affects over 55 million people globally, making the search for reliable early diagnostic tools a critical priority. The Fastball test may not provide definitive predictions regarding Alzheimer’s development, but it represents a significant advancement in understanding and detecting brain function, potentially leading to earlier access to life-extending treatments for patients.
Check out the original article here: Source link
